Skip to content
10-Q

Quarterly Report

Acorda Therapeutics, Inc.

0000950170-23-063274

← back to feed
Filed
Nov 14, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Nov 9, 2023 1.24M sh
Shares Diluted Q3 2023 · Sep 30, 2023 1.24M sh
Shares Diluted Q3 2023 · Sep 30, 2023 1.24M sh
Shares Diluted restated Q3 2023 · Sep 30, 2022 1.24M sh
Shares Diluted restated Q3 2023 · Sep 30, 2022 871K sh
Capex Q3 2023 · Sep 30, 2023 $220K
Capex Q3 2023 · Sep 30, 2022 $136K
Operating Cash Flow Q3 2023 · Sep 30, 2023 −$10.97M
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$29.99M
Cash And Equivalents Q3 2023 · Sep 30, 2023 $32.47M
Cash And Equivalents Q3 2023 · Dec 31, 2022 $37.54M
Cash And Equivalents Q3 2023 · Sep 30, 2022 $20.7M
Cash And Equivalents Q3 2023 · Dec 31, 2021 $45.63M
Stockholders Equity Q3 2023 · Sep 30, 2023 $58.96M
Stockholders Equity Q3 2023 · Dec 31, 2022 $93.62M
Current Liabilities Q3 2023 · Sep 30, 2023 $46.29M
Current Liabilities Q3 2023 · Dec 31, 2022 $37.95M
Current Assets Q3 2023 · Sep 30, 2023 $73.73M
Current Assets Q3 2023 · Dec 31, 2022 $82.12M
Total Assets Q3 2023 · Sep 30, 2023 $366.34M
Total Assets Q3 2023 · Dec 31, 2022 $395.6M
Eps Diluted Q3 2023 · Sep 30, 2023 −$7.16
Eps Diluted Q3 2023 · Sep 30, 2023 −$28.25
Eps Diluted restated Q3 2023 · Sep 30, 2022 −$11.17
Eps Diluted restated Q3 2023 · Sep 30, 2022 −$97.66
Eps Basic Q3 2023 · Sep 30, 2023 −$7.16
Eps Basic Q3 2023 · Sep 30, 2023 −$28.25
Eps Basic restated Q3 2023 · Sep 30, 2022 −$11.17
Eps Basic restated Q3 2023 · Sep 30, 2022 −$97.66
Sga Expense Q3 2023 · Sep 30, 2023 $23.15M
Sga Expense Q3 2023 · Sep 30, 2023 $67.49M
Sga Expense Q3 2023 · Sep 30, 2022 $23M
Sga Expense Q3 2023 · Sep 30, 2022 $80M
Rd Expense Q3 2023 · Sep 30, 2023 $1.21M
Rd Expense Q3 2023 · Sep 30, 2023 $4.14M
Rd Expense Q3 2023 · Sep 30, 2022 $1.38M
Rd Expense Q3 2023 · Sep 30, 2022 $4.6M
Net Income Q3 2023 · Sep 30, 2023 −$8.89M
Net Income Q3 2023 · Sep 30, 2023 −$35.09M
Net Income Q3 2023 · Jun 30, 2023 −$9.38M
Net Income Q3 2023 · Mar 31, 2023 −$16.82M
Net Income Q3 2023 · Sep 30, 2022 −$13.85M
Net Income Q3 2023 · Sep 30, 2022 −$85.06M
Net Income Q3 2023 · Jun 30, 2022 −$46.68M
Net Income Q3 2023 · Mar 31, 2022 −$24.52M
Operating Income Q3 2023 · Sep 30, 2023 −$2.52M
Operating Income Q3 2023 · Sep 30, 2023 −$17.63M
Operating Income Q3 2023 · Sep 30, 2022 −$4.99M
Operating Income Q3 2023 · Sep 30, 2022 −$35.61M
Cost Of Revenue Q3 2023 · Sep 30, 2023 $3.39M
Cost Of Revenue Q3 2023 · Sep 30, 2023 $9.69M
Cost Of Revenue Q3 2023 · Sep 30, 2022 $11.01M
Cost Of Revenue Q3 2023 · Sep 30, 2022 $25.77M
Revenue Q3 2023 · Sep 30, 2023 $27.72M
Revenue Q3 2023 · Sep 30, 2023 $79.65M
Revenue Q3 2023 · Sep 30, 2022 $33.51M
Revenue Q3 2023 · Sep 30, 2022 $87.1M